GlassScriptPhysician profile
Alyssa Dawn Hill
NPI 1265056642
$3,456.85
in general payments reported to CMS, 2019-2025
43 companies · $1,447 in 2025
The $1,447 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $383 · 2023: $802 · 2024: $825 · 2025: $1,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,875 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,875.44 |
| Education | $197.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $348.80 | 2022-2025 | |
| Pfizer INC. | $330.71 | 2022-2025 | |
| Celgene Corporation | $304.23 | 2022-2025 | Opdivo, Reblozyl |
| Incyte Corporation | $215.84 | 2022-2025 | Monjuvi, Jakafi |
| Merck Sharp & Dohme LLC | $206.14 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $173.53 | 2022-2025 | Erleada, Rybrevant, Tecvayli |
| E.R. Squibb & Sons, L.L.C. | $156.27 | 2023-2025 | Opdivo, Krazati, Opdualag |
| Seagen INC. | $145.19 | 2022-2023 | Padcev, Adcetris |
| Abbvie INC. | $94.23 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $88.20 | 2022-2025 | Enhertu, Imfinzi |
| Gilead Sciences, INC. | $84.67 | 2022-2025 | Trodelvy |
| Glaxosmithkline, LLC. | $84.64 | 2025 | Ojjaara, Jemperli, Zejula |
| Array Biopharma INC | $76.11 | 2024-2025 | Mektovi, Braftovi, Lorbrena |
| Astellas Pharma US INC | $73.86 | 2023-2024 | Xtandi, Padcev |
| Daiichi Sankyo INC. | $73.23 | 2022-2024 | Enhertu, Injectafer |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $61.67 | 2023-2025 | Cabometyx |
| Eisai INC. | $61.35 | 2025 | |
| Aveo Pharmaceuticals, INC. | $53.89 | 2025 | |
| Pharmacosmos Therapeutics INC. | $53.04 | 2024-2025 | Monoferric, Cosela |
| Bayer Healthcare Pharmaceuticals INC. | $52.27 | 2025 | |
| Adc Therapeutics America, INC. | $51.30 | 2023-2025 | |
| Genentech USA, INC. | $51.16 | 2022-2024 | Gazyva, Venclexta |
| Amgen INC. | $46.74 | 2022-2023 | Kyprolis |
| Takeda Pharmaceuticals U.S.A., INC. | $42.98 | 2022-2025 | Ninlaro |
| Genzyme Corporation | $40.94 | 2023-2025 | |
| Beigene USA, INC. | $40.24 | 2024-2025 | Brukinsa, Tevimbra |
| Rigel Pharmaceuticals, INC. | $40.03 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Lilly USA, LLC | $37.94 | 2023-2025 | Verzenio, Jaypirca |
| Pharmaessentia USA Corporation | $36.54 | 2024-2025 | Besremi |
| Servier Pharmaceuticals LLC | $35.53 | 2023-2025 | |
| Sobi, INC | $34.16 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $32.77 | 2024 | Libtayo |
| Jazz Pharmaceuticals INC. | $32.76 | 2022-2024 | |
| Taiho Oncology, INC. | $29.00 | 2025 | |
| Tersera Therapeutics LLC | $25.55 | 2025 | Zoladex |
| Tempus Ai, INC | $22.85 | 2024 | |
| G1 Therapeutics, INC. | $21.43 | 2023 | Cosela |
| Alexion Pharmaceuticals, INC. | $19.32 | 2023 | Ultomiris |
| Blueprint Medicines Corporation | $19.16 | 2023 | Ayvakit |
| Puma Biotechnology, INC. | $18.00 | 2023 | |
| Pharmacyclics LLC, An Abbvie Company | $14.57 | 2023 | Epkinly, Imbruvica |
| Emd Serono, INC. | $13.04 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $12.97 | 2023 | Onivyde, Somatuline Depot |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.